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Direct-to-Consumer Genetic Testing: Learning
from the Past and Looking toward the Future
STEPHANIE BAIR*
I. INTRODUCTION: THE HUMAN GENOME PROJECT AND THE
ADVENT OF DIRECT TO CONSUMER GENETIC TESTING
In 2003, the Human Genome Project released the completed sequence of the
human genome. 1 The media and the scientific community at the time heralded this
accomplishment as "the key to transforming medicine and understanding disease,"
predicting the usefulness of the human genome for the development of new treatments,
the customization of drugs to individual genetic profiles, and the identification of
individual propensities to develop specific diseases.' Scientists also warned, however,
that the sequencing of the human genome was simply the first step on a "long road" of
scientific research and that "immediate major breakthroughs should not be expected."3
The completion of the human genome opened a new era of human genetic and
medical research. Pursuant to this scientific advance, numerous private companies
offering what have come to be termed direct to consumer (DTC) genetic testing services
have emerged.' As the name implies, these tests are marketed directly to consumers
and can be purchased and completed without the involvement of a medical healthcare
professional.5 These tests are offered for a variety of purposes, from predicting a child's
eye color to determining an individual's response to AIDS treatment.' Most of these
tests fall within a regulatory grey area; thus, the DTC genetic testing industry has to
this point remained largely unregulated.'
Almost a decade after the human genome has been sequenced, we are beginning to
understand more about the risks and benefits of direct to consumer genetic testing. A
detailed examination of these risks and benefits suggests that recent steps by the Food
and Drug Administration (FDA) to comprehensively regulate DTC genetic tests as
* Stephanie Bair holds the following degrees: BSc. Physics, University of Prince Edward Island
(2001); Ph.D. Neuroscience, University of Utah (2008); J.D. Harvard Law School (2012).
Francis S. Collins et al., The Human Genome Project: Lessons from Large-Scale Biology, 300
Science 286 (2003).
2 Wired.com, Human Genome Complete, http'//www.wired.con/medtech/health/news/2003/04/58471,
last visited on Nov. 18, 2012.
3 Id.
4 See, e.g., Justin P. Annes et al., Risks of Presymptomatic Direct-to-Consumer Genetic Testing, 363
NEW ENG. J. MED. 1100, 1100 (2010).
5 Id
6 For example, the genetic testing service 23andMe provides information for both of these purposes
with the purchase of a 23andMe genetic "health kit." 23andMe.com, Health Reports: Complete List, https://
www.23andme.com/health/all/, last visited on Nov. 18, 2012.
7 See, e.g., Rebecca Andar Novick, One Step at a Time: Ethical Barriers to Home Genetic Testing
and Why the U.S. Health Care System is Not Ready, I I N.Y.U. J. INT'L L. & POL. 621, 624-631 (2008).
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Class III medical devices requiring premarket approval' are steps in the right direction,
and will lead to increased safety, effectiveness, and public trust of the DTC genetic
testing industry.
I. THE SCIENCE BEHIND DIRECT TO CONSUMER GENETIC TESTS
Direct to consumer genetic tests are marketed for a variety of purposes. Some tests are
specifically marketed as a means of ascertaining genetic ancestry or other relationship-
based information.9 Other tests are offered for a variety of health-related purposes."
Health-related tests generally fall into three broad categories, referred to throughout this
article as pharmacogenetic tests, predictive tests, and nutrigenetic tests, respectively.
Pharmacogenetic tests purport to provide information about the suitability and efficacy
of a particular drug for the individual consumer.II Predictive genetic tests are marketed
as a means of obtaining individualized risk assessments for the acquisition of a particular
disease or set of diseases. 2 Nutrigenetic tests provide individualized nutrition and
lifestyle information based on a consumer's genetic profile. 3 Some testing companies
offer all three of these services. 4
The science of genetic testing is based on the simple idea that an individual's personal
genetic makeup can provide a wealth of varied and valuable health-related information.
Although this is certainly true, an understanding of the specific scientific underpinnings
of these tests is necessary to understand both their strengths and limitations.
A. The Genetics of Genetic Testing
The "human genome" refers to the genetic information encoded by the twenty-
three pairs of chromosomes found in the nuclei of most cells in the human body. 5
Chromosomes are composed of two intertwining strands of deoxyribonucleic acid
(DNA), and each strand of DNA, in turn, is composed of a series of nucleotides. 16 A
nucleotide (adenine, thymine, cytosine, or guanine) in a single strand of DNA is bonded
to a complementary nucleotide on the second intertwined strand, forming a base pair. 7
Mutations in genetic information can occur in a variety of ways.' Mutations may
occur during cell division as a copy of an organism's genetic information is made and
8 In September 2010, FDA sent letters to five DTC genetic testing companies, requesting that these
companies submit premarket approval applications for their products. See FDA.gov, Medical Devices Letters
to Industry, http://www.fda.gov/MedicalDevices/ResourcesforYou/lndustry/ucm 111104.htm, last visited on
Nov. 18, 2012.
9 For example, the company Ancestry.com offers a genetic test to "help you find genetic cousins and
expand your family tree." Ancestry.com, DNA Testing by Ancestry.com, http://dna.ancestry.com/welcome.
aspx., last visited on Nov. 18, 2012.
0 This article will focus on the health-related tests.
See, e.g., Gail H. Javitt & Kathy Hudson, Public Health at Risk: Failures in Oversight of
Genetic Testing Laboratories 5 (2006), available at http://www. dnapolicy.org/images/reportpdfs/
PublicHealthAtRiskFinalWithCover.pdf [hereinafter Public Health at Risk].
12 Novick, supra note 7, at 633-34.
I d. at 632.
For example, the genetic testing service Navigenics will "analyze[] your DNA for genetic risk
markers associated with a wide variety of health conditions and medication responses," so that a consumer
can "personalize [his] health strategies." Navigenics.com, Conditions and Medication Responses, http://
www.navigenics.com/visitor/what we offer/conditions we cover/. Since the first writing of this article,
Navigenics has been acquired by Life Technologies. It appears that Navigenics will not continue to offer
genetic testing services.
'5 ELDRA PEARL SOLOMON ET AL., BIOLOGY G-16 (4th ed. 1996).
16 Id. at 272-77.
17 Id.
'1 Id. at 303-309.
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included in the new cell. 9 Genetic information may be added or deleted from a gene,
or base pairs may be rearranged within a gene.2' During this copying process, single
nucleotides may also be miscoded (for example, an adenine may be replaced by a
cytosine), leading to what are known as single nucleotide polymorphisms (SNPs).1
SNPs are inherited from parent to child, and continuing research is divining correlations
between the identity of specific SNPs and various health-related measures, such as
susceptibility to certain diseases or responsiveness to certain drugs.
2
Companies currently offering DTC health-based genetic tests rely on SNPs to provide
inexpensive genetic testing. Rather than sequencing an individual's entire genome, which
is still infeasible due to cost, DTC genetic testing companies use a "SNP chip" to target
particular SNPs in an individual's genetic material.3 By determining the identity of a
range of an individual's SNPs, these companies, drawing on current scientific research
associating particular SNP profiles with health-related measures such as susceptibility
to disease, purport to provide individualized health information to the consumer.24 Each
type of genetic test uses a SNP chip to obtain genetic information and then draws on
research from the relevant fields to draw potentially useful conclusions.
B. Pharmocogentic Tests
Pharmocogenetic tests use current research associating particular genetic profiles
with responsiveness to specific drugs to provide individualized drug responsiveness
information to the consumer.25 For example, certain SNPs in the CYP2C9 gene have
been found to be associated with an individual's ability to metabolize Warfarin, a
drug prescribed as a blood thinner.26 This association has been well-documented, and
the FDA has stated that genetic testing could play an important role in determining
individualized dosages of Warfarin. 27 The DTC genetic-testing company 23andMe, Inc.
provides information to consumers about predicted Warfarin responsiveness based on
the consumer's variant of the CYP2C9 gene.28 The company also provides predictive
response information for 18 other treatments and drugs, ranging from information
regarding an individual's susceptibility to heroin addiction, to information about
an individual's predicted response to Hepatitis C treatment. 29 Although some of the
associations upon which this information is based-including the association between
Warfarin metabolization and CYP2C9 variants-are well-grounded in many years of
19 Id.
20 Id.
21 JOHN M. BUTLER, FORENSIc DNA TYPINO: BIOLOGY, TECHNOLOGY, AND GENETICS OF STR MARKERS 182
(2d ed. 2005).
22 Id.
23 R. RAPLEY R. & S. HARBRON, MOLECULAR ANALYSIS AND GENOME DISCOVERY (2004).
24 23andMe, for example, states that their DNA chip "genotypes hundreds ofthousands of SNPs at one
time," and the company also "hand-pick[s] tens of thousands of additional SNPs of particular interest from
the scientific literature and adds their corresponding probes to the DNA chip... to provide personal genetic
information." 23andMe.com, How Does 23andMe Genotype my DNA?, https://www.23andme.com/you/
faqwin/chip/, last visited on Nov. 18, 2012.
21 See, e.g., Javitt & Hudson, Public Health at Risk, supra note 11.
26 See, e.g., Wadelius et al., Association of Warfarin Dose with Genes Involved in its Action and
Metabolism, 121 Hum. Genet. 23, 23-34 (2004).
27 FDA.gov, http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathlnitiative/
CriticalPathOpportunitiesReports/UCM077254.pdf, RIO, last visited on Nov. 18, 2012.
21 23andMe.com, Warfarin Sensitivity-Sample Report, https://www.23andme.com/health[Warfarin-
Coumadin-Sensitivity/. last visited on Nov. 18, 2012.
29 23andMe.com, Health Reports: Complete List, https://www.23andme.com/health/all/, last visited
on Nov. 18, 2012.
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research, other associations are much more tentative and are based only upon a single
recent study.30
C. Predictive Tests
Predictive tests, as their name implies, are marketed for the purpose of "predicting"
whether an individual will develop a specific disease in his lifetime based on his genetic
profile.3 When evaluating genetic susceptibility for disease, an important distinction
must be made between the Mendelian, or monogenic, diseases on the one hand and
the complex, or polygenic, diseases on the other.32 Monogenic diseases are hereditary
diseases that are caused by a mutation in a single gene.33 Some monogenic diseases
exhibit complete penetrance, meaning that all individuals carrying the relevant mutation
will exhibit symptoms of the disease at some point in their lives.3 Familiar examples
of monogenic diseases include Huntington's disease and cystic fibrosis. 5 In contrast,
complex or polygenic diseases do not exhibit Mendelian inheritance patterns and are
thought to arise due to a complex interaction of several genetic and environmental
influences.36 Associations linking particular genetic mutations to polygenic disease
susceptibility are necessarily probabilistic; because the development of the disease
depends on the interaction of a number of known and unknown factors, the most that
can be done through genetic testing is to estimate increased risk of the disease. This
estimate is derived from population studies comparing individuals carrying a specific
variant of a gene of interest with others who do not carry that specific variant.37 Common
examples of polygenic diseases include heart disease and Type II diabetes.38
Many DTC predictive tests available on the market today evaluate an individual's
susceptibility to polygenic rather than monogenic diseases. Thus, these tests can only
provide estimations of risk based on population data.39 This is again accomplished by
linking SNP profiles in the individual consumer with associations between particular
SNPs and susceptibility to certain diseases. The genetic testing service 23andMe offers
predictive information for 95 diseases and conditions, including "back pain," attention
deficit hyperactivity disorder, schizophrenia, lung cancer, and heart disease.
4
D. Nutrigenetic Tests
Nutrigenetic tests are similar to predictive tests in that they analyze an individual's
risk of disease based on his genetic profile. The testing company then goes one step
further by providing individualized diet and lifestyle recommendations based on this
analysis, with the goal of reducing the individual's risk. 4' For example, if the genetic
test determined an individual to be at increased risk for developing heart disease,
3o For example, 23andMe's association between genetics and response to a subset of antidepressant drugs
is based on a single study. 23andMe.com, Antidepressant Response- Sample Report, https://www.23andme.
com/health/Antidepressant-Response/, last visited on Nov. 18, 2012. A single study, without at least a
confirmation trial, is insufficient to establish the association on which 23andMe relies.
3' See, e.g., Novick, supra note 7, at 633-34.
32 MICHAEL WINK, AN INTRODUCTION TO MOLECULAR BIOTECHNOLOGY 456 (2006).
33 Id.
34 MUIN J. KHOURY ET AL., HUMAN GENOME EPIDEMIOLOGY 38 (2d ed. 2010).
35 Id.
36 Wink, supra note 32.
" D.J. Galton & G.A.A. Ferns, Genetic Markers to Predict Polygenic Disease: a New Problem for
Social Genetics, 92 Quart. J. Med. 223 (1999).
38 Id.
s9 Galion & Ferns, supra note 37.
4 23andMe.com, Health Reports: Complete List, https://www.23andme.com/health/all/, last visited
on Nov. 18, 2012.
41 See, e.g., Novick, supra note 7, at 632.
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the test results would return diet and lifestyle recommendations based on the current
scientific understanding of reducing risk for this disease. Thus, the consumer would
be advised to exercise, avoid tobacco, and eat a diet low in saturated fat and full of
fruits and vegetables.
Il. BENEFITS AND DRAWBACKS OF DTC GENETIC TESTING:
IMPLICATIONS FOR REGULATION
For many years, scientists and policymakers have discussed the potential benefits
and drawbacks of DTC genetic testing.42 The concerns of those who argue for increased
regulation of DTC genetic tests-foremost among these, concerns about accuracy and
clinical effectiveness of the tests and patient use of results-provide a strong rationale
for increased regulation.43 Those who believe that DTC genetic tests should continue
to be offered with minimal regulatory intervention often point to the benefits of patient
autonomy, privacy, and discouragement of product development. 44 However, a closer
inspection of these potential benefits reveals that they may not actually be achieved
through the unregulated marketing and use of DTC genetic tests. In fact, patient
autonomy, privacy, and product development, along with increased product safety and
accuracy, may be enhanced, or at least not undermined, by increased regulation.
A. Concerns with DTC Genetic Tests
1. Consent
A threshold concern with DTC genetic tests involves the concept of informed
consent. 5 The idea of obtaining informed consent from a patient before proceeding with
a medical procedure or treatment is one that is well-established in health jurisprudence. 4
A doctor must discuss the risks and benefits of a proposed procedure with a patient and
allow the patient to ask questions. 47 A doctor must also disclose possible alternative
procedures and the risks and benefits of such alternatives. 48 The rationale behind such
a requirement is the protection of an individual's freedom to choose those procedures
which she will undergo after having considered the relevant information.49 Empirical
studies have shown that both physical and psychological benefits accrue to a patient
who participates in treatment via an informed consent relationship with a health care
professional .0
DTC genetic tests pose a potential threat to the established model of informed
consent." A typical DTC "patient" orders the genetic test from a website. Although
most companies offering DTC genetic tests include detailed information about the
2 See, e.g., A.L. Maguire et al., Personal Genome Testing, 330 Science 181-82 (2010).
4 Id The strongest call for increases regulation of DTC genetic tests comes from the scientific and
medical community. See, e.g., Id.
' Id. Those who oppose increased regulation of DTC genetic tests include, unsurprisingly, the companies
that offer such services, as well as various consumer groups. See, e.g., Id.
" See, e.g., Dorothy C. Wertz & John C. Fletcher, Communicating Genetic Risks, Sci, Tech., & Human
Values, Jun. 1988, at 60.
46 See, e.g., L.B.Andrews, TheRationaleBehindthe Informed Consent Doctrine, I J. Med. Prac. Mgmt.
59-65 (1985). This concept is also referred to as the "leamed intermediary doctrine." See, e.g., Jeffrey J.
Wiseman, Another Factor in the "'Decisional Calculus, " The Learned Intermediary Doctrine, The Physician
Patient Relationship, And Direct-To-Consumer Marketing, 52 S.C. L.R. 993 (2001).
47 Id.
48 Id.
49 Id.
50 Id.
"i Novick, supra note 7, at 636.
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testing process on their websites, this information is not a substitute for a conversation
with a health care professional about risks and benefits. Not surprisingly, the content
of these websites is written to persuade as well as to inform; although the benefits of
undergoing a test are highly touted, there is seldom any mention of risk." Also notably
missing from the content of these sites is information related to the alternatives of either
obtaining a genetic test from a health care provider, or foregoing the test altogether. 3
Finally, in some unfortunate cases, the information provided on these websites may be
deliberately misleading.54
Proponents of DTC genetic tests may argue that the risks of undergoing these tests
are minimal and thus the information obtained via a company's website is sufficient
to make an informed decision. As will be discussed, however, potential emotional and
physical harms can result either directly from test results, or indirectly through patient
misinterpretation or misuse of results.5 These risks are magnified when a patient does
not consult with a health care professional in any stage of the testing process. 6
Some of the leading DTC genetic testing companies do offer over-the-phone (or
over-the-web) genetic counseling services; however, this is insufficient as a mechanism
for true informed consent for a variety of reasons. First, the counseling is often not
mandatory." Given that many of the consumers of DTC genetic testing services may
be those who have particularly strong privacy or autonomy concerns,5 it is likely that a
majority of these consumers will choose not to discuss their personal medical concerns
with a counselor. Second, incentives offered to consumers by the companies with regard
to counseling services might disrupt the informed consent process. For example, the
popular DTC genetic testing company 23andMe offers free genetic counseling services
only after a patient has purchased access to the test.5 When trying to decide whether or
not to test, this is clearly unhelpful to a consumer. Finally, when a company does offer
genetic counseling services prior to testing, these services may be tainted by the same
bias towards testing that is evidenced on the company's websites. Although potentially
biasing financial incentives exist in any patient-provider relationship, these incentives
are more troubling when unbuffered, as they would typically be in most healthcare
situations, by insurance and other intermediaries. 60
11 For example, the genetic testing service deCodeme's website exclaims the health benefits of using
its service and prominently includes patient testimonials on its webpage; the only disclaimer is found at the
very bottom of the page in 8-point font of an almost illegible light grey against a white background. It states
that deCodeme is for informational purposes only and "should NOT be used for medical decision making
without consulting your physician." deCodeme.com, Genes and Health, http://www.decodeme.com/genes-
and-health, last visited Nov. 18, 2012.
53 Of the major testing companies 23andMe, deCodeme, and Navigenics, there is no mention on the
companies' respective websites of the option of not testing.
4 See Gregory Kutz, Direct to Consumer Genetic Tests: Misleading Test Results are Further
Complicated by Deceptive Marketing and Other Questionable Practices, GAO 10-847T, at 15 (2010).
1s See, e.g., Alberto Gutierrez, FDA official, Interview with the New York Times, (http://www.nytimes.
com/2010/06/121health/12genome.html? r=l |&scp 1&sq-gutierrez%2OFDA%2Ogenetic%20testing&st-cse
(June 11, 2010), last visited Nov. 18, 2012.
56 Id.
7 None of the three major genetic testing services companies (23andMe, deCodeme and Navigenics)
requires mandatory genetic counseling, although they all offer these services to varying degrees.
5 See infra page 424-426, for a discussion of the potential benefits of home genetic testing.
9 23andMe.com, 23andMe Enlists Informed Medical Decisions to Make Independent Genetic
Counseling Services Available to Customers, https://www.23andme.com/about/press/20100603/, last visited
Nov. 18, 2012.
' Novick, supra note 7, at 640.
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2. Accuracy and Utility Concerns
a. Clinical Effectiveness and Accuracy
Once a patient decides to proceed with a genetic test, concerns of test accuracy and
clinical usefulness move to the forefront. These concerns are especially apparent with
health-based tests purporting to provide "predictive" information about individual
disease risk, and inhere from the probabilistic nature of risk prediction for polygenic
diseases.6 Scientists have reached a general consensus that current known associations
between a given SNP and a given disease are generally so attenuated that they provide
little useful predictive information. 62 For example, a 2008 paper by David Altshuter el
at., evaluating the usefulness of the type of studies relied on by DTC genetic testing
companies (referred to in the paper as genome-wide association studies, or GWAS)
found that "variants so far identified by GWASs together explain only a small fraction
of the overall inherited risk of each disease (for example, -10% of the variance for
Crohn's [Disease] and -5% for [Type 2 Diabetes]). The primary value of [these
associations] is not risk prediction, but providing novel insights about mechanisms of
disease."63 Although the authors did not completely dismiss the future clinical utility of
predictive genetic tests, they determined that "the extent to which genetic information
will figure in 'personalized medicine' will depend on whether predictive accuracy
beyond conventional measures can be attained, and whether there are interventions
whose effectiveness is improved by knowledge of a genetic test." 6 Similarly, in a review
article evaluating the relevant scientific literature Teri Manolio explained that "what is
becoming clear from these early attempts at genetically based risk assessment is that
currently known variants explain too little about the risk of disease occurrence to be of
clinically useful predictive value. ' 65 The author of this article came to the conclusion
that "patients inquiring about [GWAS] testing should be advised that at present the
results of such testing have no value in predicting risk and are not clinically [useful]. 66
These voices in the scientific community are warning that although predictive testing
may play a future role in medicine, the science has not yet evolved to the point where
the kinds of information that DTC genetic testing services are purporting to offer can
be reliably obtained and usefully applied.
b. The Importance of External Factors in Predicting Disease
Because DTC genetic tests are focused on predicting risk for polygenic diseases,
which result from a number of unknown environmental and genetic factors in addition
to the genetic association identified and relied upon by the testing service, personal
context is extremely important in interpreting test results. 67 In many cases, this external
contextual information is an even better predictor of disease than the association
relied upon by the testing service. For example, 23andMe, Inc. offers a test for genetic
susceptibility to lung cancer, although it is well known that the degree of risk for lung
cancer attributable to genetic factors is dwarfed by the risk introduced by a patient's
11 See, e.g., David Altshuter et at., Genetic Mapping in Human Disease, 322 Science 881, 881 (2008).
62 Id.
63 Id at 885, 886.
61 Id. at 887.
6' Teri A. Manolio, Genomewide Association Studies and Assessment of the Risk of Disease, 363 New
Eng. J. Med. 166, 173 (2010).
16 Id. at 173-74.
67 Carla G. van El & Martina C. Cornel, Genetic Testing and Common Disorders in a Public Health
Framework. Recommendations of the European Society of Human Genetics, 176 Eu. J. Hum. Genetics 1, 3
(2011).
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status as a smoker or non-smoker.68 Family history of disease also often provides a better
prediction of susceptibility to a given disease.69 A DTC genetic test can be misleading
insofar as it does not evaluate or report to the consumer (and in some cases the testers
may not even be aware of the nature of) relevant external information that may have a
much greater impact on an individual's susceptibility to disease.
c. Effects of Ethnicity and Other Factors on Test Validity
Even to the extent that the numbers provided by DTC genetic health tests have
meaning, the meaning is limited to those whose ethnicity, approximate age, and gender
match the underlying populations (usually white, middle aged men) on which the
association studies are based."° The findings of these studies are heavily dependent on
such factors.7 Although some of the DTC testing companies' websites mention this
caveat, they do not explicitly state that their tests are not recommended for certain
populations, although for these groups most of the test results may be essentially
meaningless. 2
d. Intra-Industry Variation in Test Results
These fundamental concerns about the predictive value of DTC genetic tests are
exacerbated by intra-industry variation in test results.7 3 The Government Accountability
Office (GAO) released a report on DTC genetic testing services on July 22, 2010.14
Among its findings, the report determined that there was a lack of standardization of
test results among companies.75 In other words, an individual testing with two different
companies might be told that he is at increased risk for a particular disease by one
testing company and that he is at decreased risk for the same disease by another testing
company.7 6 The report also cited potentially even more troubling concerns in the DTC
genetic testing industry, including deceptive marketing practices and erroneous medical
management advice. 77 These considerations further undermine the potential utility of
such tests.
e. The Possibility of Conflicting Recommendations
Finally, scientists worry that the nature of the DTC predictive tests currently being
offered, which screen for predisposition to many conditions at a single time, might result
in conflicting recommendations that are confusing or even dangerous to a consumer.78
For example, a nutrigenetic/predictive test might reveal that a consumer is predisposed
68 Although 23andMe's website makes clear that smoker status is the best predictor of lung cancer,
similar situations could arise in which research has not yet revealed external risk factors whose predictive
value is significantly greater than known genetic contributors.
69 van El & Comel, supra note 67.
70 Altshuter et al., supra note 61, at 884.
71 Id.
72 Of the major testing companies 23andMe, deCodeme, and Navigenics, only 23andMe mentions
ethnicity. It does so in the context of specific tests. For example, it states on the prostate cancer information
page that because a study including Japanese Americans was inconclusive, "the exact association in populations
with Asian ancestry still needs to be confirmed." Presumably, this was only mentioned because a study in
Asian Americans was in fact performed. There is no mention of ethnicity for other studies performed in only
a single ethnic group. 23andMe.com, Prostate Cancer Sample Report, https://www.23andme.com/health/
Prostate-Cancer/, last visited Nov. 18, 2012.
" Kutz, supra note 54, at 5.
74 Id.
75 Id.
76 Annes et al., supra note 4, at 1100.
7 Kutz, supra note 54, at 15.
7 Manolio, supra note 65, at 173.
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both to osteoarthritis and Type II Diabetes. The consumer might of his or her own
volition or upon the recommendation of the testing company decide to begin taking
Glucosamine, a nutritional supplement that has been reported to help prevent and ease
the symptoms of osteoarthritis.79 However, Glucosamine may affect insulin sensitivity
in certain populations, potentially exacerbating diabetic symptoms or precipitating the
onset of diabetes.8" DTC genetic testing companies are currently unprepared to deal
with such potential complexities arising from the testing process. 8'
3. Patient Interpretation and use of Results
Even if a consumer could be assured of receiving accurate, consistent, and non-
misleading information from a DTC genetic testing service, a proposition that has been
seriously questioned in the previous section, there remain health concerns arising from
the patient's interpretation and use of such results.
a. Patient Interpretation
First, the very nature of these tests gives rise to a problem of consumer interpretation.
As previously discussed, these tests rely on association studies linking particular SNPs
to incidence of a particular trait (such as disease or reaction to a drug) in the general
population. The results of these studies yield a very specific type of statistical information
that has meaning for researchers in the field, but may be meaningless (or at the very
least difficult to understand and interpret) for an individual consumer.82 That is not to
say that consumers could not or should not be educated in the nuances of statistics and
thus learn to interpret their test results in a sophisticated manner. However, when these
problems of interpretation are combined with the accuracy problems outlined above, we
may question whether it is worth undertaking this educational effort when the end result
will be sophisticated interpretation of results that have little value in the first instance.
In the meantime, misinterpretation or misuse of results could lead to serious health-
related concerns, such as adverse psychological response or inappropriate patient action.
b. Psychological Response to Test Results
One health-related concern is the possibility that a consumer will be emotionally
devastated by test results, and will lack the resources in a home testing environment to
obtain appropriate psychological support. This argument is intimately related to the issue
of informed consent.83 Recent research, however, suggests that this particular concern
may be unfounded.84 An empirical study performed by Cinnamon Bloss and colleagues
found that consumers undergoing DTC genetic testing did not score significantly higher
on stress-related indicators upon learning that they were at increased risk for a particular
disease such as heart disease or cancer.8" The study does suggest, however, that these
results may be partly attributed to the sample utilized in the study, since subjects who
completed the study were self-selecting to some degree and likely had an above-average
7 McAlindon T.E. at al., Glucosamine and Chondroitin for Treatment of Osteoarthritis: a Systematic
Quality Assessment and Meta-Analysis, 283 J. Am. Med. Ass'n, 1469 (2000).
80 Joseph G. Yu eta ., The Effect of Oral Glucasamine Sulfate on Insulin Sensitivity in Human Subjects,
26 Diabetes Care 1941 (2003). This study found that insulin sensitivity was reduced in obese patients,
although it did not find an effect in overall populations.
8' Manolio, supra note 65, at 173.
82 Altshuter et al., supra note 62.
s See, e.g., Shelly Cummings, The Genetic Testing Process: How Much Counseling Is Needed?, 18
J. Clinical Oncology 60, 62 (2000).
84 Cinnamon S. Bloss et al., Effect of Direct-to-Consumer Genomewide Profiling to Assess Disease
Risk, 364 New Eng. J. Med. 524 (2011).
85 Id.
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understanding of genetic testing. 6 Continued empirical research will be helpful in
gauging the extent to which DTC genetic testing raises concerns about psychological
harm resulting from adverse test results.
c. Patient Action in Response to Test Results
Perhaps more pressing than the concern that consumers will be devastated by adverse
information related to their health is the concern that consumers will be falsely reassured
by positive information. A finding of "no increased risk" certainly does not mean that
a consumer exhibits zero risk for contracting a disease, especially since environmental
and untested genetic factors may play an even greater role in disease onset than the
tested marker. However, a consumer may psychologically rely on such information
and may undergo increased psychic trauma if he or she contracts the disease. Even
more dangerous is the possibility that the patient will adversely change her behaviors
in reliance upon such information.87 23andMe, Inc., for example, tests patients for both
increased risk of heroin addiction and HTV resistance." A result of "no increased risk
of heroin addiction" or "HIV resistant" may lead a patient to engage in risky behaviors
such as drug use or unprotected sex out of a false sense of immunity from the dangers
of addiction or infection.
Related to this concern is the concern with pharmacogenetic testing that a patient
will use test results to make treatment and dosage decisions independent of consultation
with a health care professional. The testing service 23andMe offers predictive response
information for 19 treatments and drugs, including predicted response to Hepatitis C
treatment. 89 A consumer receiving a result that he has reduced chances of responding
to such treatment may discontinue the treatment without consulting his physician. This
is a particularly likely possibility given that the treatment entails uncomfortable side
effects. Even when a relationship between predicted responsiveness to a drug and a
specific genetic profile is well-established and has been found to be of clinical usefulness,
such as that between Warfarin metabolism and a SNP on the CPY2C9 gene, dosage is
a complex calculation that relies on factors such as patient weight and age, and is best
performed by a physician.9"
This concern is more than just hypothetical. A recent study found that "40% of
participants with genetic test results indicating increased risk for Alzheimer's disease
reported increasing their use of medications or vitamins, compared with 20% of those
whose results did not indicate increased risk."'"
4. Economic Concerns
Perhaps less pressing than public health concerns, but equally deserving of attention,
are the economic consequences of engaging in DTC genetic health testing, both for
individual consumers and society as a whole.
8 Id.at531.
7 See, e.g., Alberto Gutierrez, FDA official, Interview with the New York Times, http://www.nytimes.
com/2010/06/12/health/I 2genome.html? r- I &scp-=1 &sq=gutierrezo20FDA%20genetic%20testing&st-cse
(June 11, 2010), last visited Nov. 18, 2012.
8 23andMe.com, Health Reports: Complete List, https://www.23andme.com/health/all/, last visited
Nov. 12, 2012.
89 23andMe.com, Health Reports: Complete List, https://www.23andme.com/health/all/, last visited
Nov. 12, 2012.
o See, e.g., Maguire et al., supra note 42.
S. Chao et al., Health Behavior Changes After Genetic Risk AssessmentforAlzheimer Disease: the
REVEAL Study, 22 Alzheimer Dis. Assoc. Disord. 94 (2008).
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a. Waste of Consumer Money
The GAO study that found serious problems with the accuracy and marketing of DTC
genetic health tests concluded that such tests at worst constitute a risk to consumer health
and at best are a waste of consumer money.92 This is not merely a trivial concern, given
that the cost of testing ranges from hundreds to thousands of dollars per consumer."
b. Effects on the Healthcare System
A second economic concern expressed by health care professionals is that consumers
undergoing DTC genetic health tests will subsequently unnecessarily undergo additional
tests, screenings, and physician consultations, thereby taxing the scarce resources of the
healthcare system.94 For example, an individual discovering that she is at increased risk
for breast cancer may demand additional mammograms not currently indicated for her
demographic group. However, the Bloss study tracking individuals' stress responses to
the results of genetic health tests found that individuals receiving genetic testing did not
generally undergo more screenings or tests subsequent to receiving personalized risk
information.95 Further, it could be argued that such screenings might actually prove useful
and save the healthcare system money in the long run by increasing detection among
high-risk groups identified by genetic testing. Thus, it is unclear what the consequences
of wide-spread use of genetic testing would be on the healthcare system as a whole.
c. Physician Liability
Finally, doctors have expressed concern that widespread use of DTC genetic health
tests might give rise to increased physician liability.96 This could occur, for example,
if a patient feels that a doctor did not respond appropriately to the patient's disclosure
of test results (for example, by ordering further tests or screenings) and thus failed to
meet the proper standard of care. This could occur although the doctor may not have
the information necessary to appropriately interpret the genetic test results, or may
have a better understanding of the limitations of such tests than the patient himself.
For example, a doctor may place a patient on a particular regimen of Hepatitis C
treatment although genetic tests reveal that the individual may not respond optimally
to such treatment because the doctor is also considering other information such as age,
weight, the severity of illness, and the availability of other treatments. Although genetic
tests can potentially provide relevant information that may help a doctor come to an
ultimate decision, great uncertainty for doctors would result if DTC genetic tests could
be introduced to establish a standard of care, especially given the extreme limitations
of the information provided by such tests.97
92 Kutz, supra note 54.
9 23andMe charges $200 for their service, while deCodeMe charges $2000. Navigenics does not
include pricing information on its website.
' Manolio, supra note 65, at 174.
9 Bloss et al., supra note 84.
96 Annes et al., supra note 5, at 1101.
9 See, e.g., Kathleen A. Mahoney, Malpractice Claims Resulting from Negligent Preconception
Genetic Testing: Do These Claims Present a Strain of Wrongful Birth or Wrongful Conception, and Does
the Categorization Even Matter, 39 Suffolk L. Rev. 773 (2006) for a discussion of physician liability for
negligence in the context of preconception genetic testing.
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B. Potential benefits of DTC Genetic Tests
1. Patient Autonomy
One of the foremost arguments forwarded in support of health-based DTC genetic
tests involves the promotion of patient autonomy.98 There has been a trend in recent years
for patients to become increasingly involved in the promotion of their health in the areas
of both diagnosis and treatment.99 Allowing consumers to access DTC genetic testing
services independently of a physician is, arguably, the next step in encouraging patient
engagement and participation in health care. However, this argument has serious flaws.
First, in order for a patient to truly make an independent decision regarding his health,
he must have sufficient unbiased information to make an informed decision, something
this article has argued is seriously lacking in the context of DTC genetic testing. Second,
even to the extent that a patient exercises autonomy in choosing to undergo DTC genetic
health testing, this autonomy is subsequently limited when the patient is unable, due to
a lack of appropriate information, context, and sufficiently predictive results, to make
informed treatment decisions based on the results of such testing.' 0
Although DTC genetic testing may not provide a meaningful opportunity for
autonomous decision-making in the realm of medical treatment, it can be argued that
such testing may nevertheless encourage individuals to adopt healthier lifestyles so as
to minimize the risks of contracting a particular disease. Such a result would indeed
grant patients an opportunity for autonomy in making lifestyle decisions, and would also
accrue benefits to society as a whole, reducing health care costs through preventative
action and increasing the overall health and well-being of those who respond to the
tests in this way. The empirical study performed by Bloss and colleagues, however,
found that individuals undergoing DTC genetic health testing and finding themselves
to be at risk for a particular disease (such as heart disease) generally did not respond by
implementing healthy and appropriate lifestyle changes.' An important exception to
this surprising result was found for those who discussed their test results with a doctor:
these individuals did in fact implement healthy lifestyle changes. 02 Although it cannot
be ruled out that individuals in this subgroup were generally more health-motivated
overall (and thus were more likely both to talk to their physician and to implement
healthy lifestyle changes), this finding generally supports the idea that autonomy may
mean little without appropriate context and guidance.
Even if a patient were in a position to independently choose appropriate medical or
lifestyle interventions upon receiving his test results, it is not clear that such interventions
are available. 03 For example, in many cases doctors are uncertain as to the appropriate
intervention for slightly increased risk of a disease as opposed to greater risk or onset of
the disease itself.' Further, in some cases there are no medically accepted preventative
measures to take, even for those who are almost certain of contracting a disease (this
is the case with both Alzheimer's disease and Huntington' s disease, for example).0 5
A patient might be unduly distressed to learn that although she is at increased risk for
a disease, there is nothing she can do about it.
11 Novick, supra note 7, at 641.
SId.
'
0 0 Id.
0 Bloss et al., supra note 84 at 529.
102 Id. at 531.
103 van El & Cornel, supra note 67.
104 Id.
1o5 Id.
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2. Genetic Privacy
An argument often forwarded by proponents of DTC genetic testing and related
to the issue of patient autonomy is that DTC genetic tests provide the opportunity for
increased privacy and control over an individual's personal genetic information.1
6
Such a view reflects concerns, arising with the sequencing of the human genome, that
an individual's personal genetic information might be used by insurance companies,
employers, the government, and others, without the permission and to the detriment
of the individual." Such concerns are valid, and have provoked the response of
the federal government. In 1995, former President Bill Clinton issued an executive
order prohibiting the federal government from using personal genetic information for
employment purposes.0 " This order did not extend to private employers, but many
states subsequently enacted similar legislation that in some cases extended the reach
of the executive order to insurance companies.0 9 Further, in 2008, former President
George W. Bush signed the Genetic Information Nondiscrimination Act (GINA)."'
GINA provides for more comprehensive federal protection of genetic information,
and includes prohibitions on the use of genetic information by private employers in
making employment decisions and health insurance companies in making decisions to
raise individual premiums or deny benefits."' This legislation still contains some gaps
(for example, it does not cover life insurance or disability insurance), and some have
exhibited concerns about enforcement, but generally the reaction of concerned groups
to the enactment of GINA has been positive." 2
Although GINA clearly does not address all the concerns of those who worry about
privacy of genetic information, to the extent that GINA addresses these concerns,
the subsequent need to turn to home genetic testing as a self-help measure is thereby
lessened. Further, it is not clear that turning to DTC genetic testing fully solves the
privacy problem either. Although the major DTC genetic testing companies reassure
customers with promises of utmost privacy,"3 it is not difficult to imagine situations in
which this information might be inadvertently or intentionally released to third parties.
DTC genetic testing companies are not regulated entities under the privacy provisions
of the federal health care statute, the Health Insurance Portability and Accountability
Act of 1996 (HIPAA)."" Thus, they are not required by law to follow the rigorous
guidelines governing protection and release of personal health information in other
contexts. Further, it is unclear what will happen to this data if a company is sold, merges
116 Novick, supra note 7, at 641.
107 Id.
"I National Human Genome Research Institute, Genetic Discrimination Fact Sheet, http://www.genome.
gov/10002328, last visited Nov. 18, 2012.
109 Id,
"I National Human Genome Research Institute, Genetic Information Nondiscrimination Act of 2008,
http://www.genome.gov/10002328#3, last visited Nov. 18, 2012.
"I Id.
12 Amy Harmon, Congress Passes Bill to Bar Bias Based on Genes, N.Y. Times, May 2, 2008, at Al.
"3 For example, the Navigenics website reassures customers with the rather disturbing statement
that "unlike some other companies, we do not sell or share your genetic information," implying that some
companies do in fact engage in these activities. Navigenics.com, What we Offer, http://www.navigenics.corm/
visitor/what we offer.
U4 See Health Insurance Portability & Accountability Act of 1996, 29 U.S.C.A. §1181 et. seq.
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with another company, or is otherwise dissolved. 5 Thus, the popular perception that
genetic information is 'safer' or 'more private' in the hands of private companies than
it is in the public health care system may well be baseless.
3. Ex ante Effects on Innovation
Finally, some who see the future potential in DTC genetic testing argue that overly
stringent regulation of these tests would amount to an effective ban of the tests." 6 In
addition to eliminating the availability of such tests to those who choose them, such
a result would also have the consequence of inhibiting product development and
improvement.17 This concern is particularly salient given that although scientists are
doubtful about the current utility of DTC genetic tests, many concede that further
scientific developments could lead to increased clinical usefulness." 8 However, much
of the scientific research on which the increased utility of the tests will rely is basic
research that is likely to be performed not by the genetic companies themselves, but
by government-sponsored and university research labs." ' These companies already
rely heavily on this type of independent research for the current utility of their tests,
and it is doubtful that they will begin to undertake independent research to validate or
improve the utility of their product unless required to do so by regulation. Further, if
and when the science does advance to a point at which DTC genetic tests are deemed
to be of clinical utility, it is important that the public's trust in such tests has not been
undermined by a long proliferation of testing products of doubtful utility. 2 °
C. Summary
Although it is currently unclear whether some of the concerns regarding DTC genetic
testing (for example, concerns about economic effects on the healthcare system) are well-
founded, other concerns, such as those regarding test accuracy and potential response
of patients to test results, are clearly grounded in empirical research and pose pressing
public health issues that should be addressed. Further, the potential benefits of DTC
genetic testing, such as patient autonomy and patient privacy, are subject to important
caveats. The clearest benefit of such testing, product development, would likely not
be greatly harmed by increased regulation, since the current and future utility of these
products depends heavily on outside research.
IV. CURRENT REGULATION OF DTC GENETIC TESTS
Given the important and serious health and safety concerns with DTC genetic tests,
the current regulatory landscape for these tests is inadequate. This landscape is filled
with grey areas and uncertainty. Several entities currently have jurisdiction to regulate
15 See James P. Evans et al., Preparing for a Consumer-Driven Genomic Age, 363 New Eng. J. Med.
1099 (2010). Providing a prime example of this situation is the case of Navigenics, which, since the first
writing of this article, has been acquired by Life Technologies, Inc., a "global biotechnology company."
Navigenics assures its customers that the company "remains committed to our founding principle of protecting
the privacy and security of our members' genetic information." http://www.navigenics.com/. Navigenics
also states that "all customer information will be protected and handled according to regulatory guidelines."
http://www.navigenics.com/visitor/aboutus/acquisition faqs//, last visited Nov. 18, 2012.
"6 See, e.g., Maguire et al., supra note 42.
117 Id.
s See, e.g., Altshuter et al., supra note 61.
"9 The correlations between SNPs and health measures on which these tests rely are all performed by
outside parties. Further, the DNA chip on which these services rely is a technology that was first developed
and used by researchers in a medical college. Leonard H. Augenlicht & D. Kobrin, Cloning and Screening
of Sequences Expressed in a Mouse Colon Tumor, 42 Cancer Research, 1088-1093 (1982).
0 Van El & Comel, supra note 67.
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genetic testing, and yet DTC genetic health testing has until recently largely slipped
through the cracks of these overlappingjurisdictions. Only recently has the FDA begun
asserting increased control over the producers and marketers of DTC genetic tests.12'
A. CLIA regulation
The Clinical Laboratory Improvement Amendments (CLIA) grant the Centers for
Medicare and Medicaid Services (CMS) authority to regulate laboratory testing of human
specimens for the diagnosis and/or treatment of disease, including genetic testing. 2 A
laboratory wishing to perform such tests must thus obtain a federal certificate of approval
before doing so.'23 Under this regulatory scheme, tests are classified into one of three
categories: waived, moderate complexity, and high complexity.'24 Tests in the waived
category are simple tests that have negligible likelihood of a false result and that pose
no risk to the patient. 5 Moderate and high complexity tests are ranked according to a
set of criteria that includes the degree of technical knowledge and individual judgment
required to perform the test and reliability of results. Genetic tests thus qualify as "high
complexity" tests. 6
Although classified as a high complexity test, genetic testing is not subject to all of
the stringent proficiency requirements required of other high and moderate complexity
tests.'27 Generally, moderate and high complexity tests must follow quality assurance
programs and undergo proficiency testing.'28 Proficiency testing, in turn, is based on
a categorization system of specialties and subspecialties of scientific expertise, each
with its own proficiency standards to which a lab seeking certification in that area must
comply. 9 The proficiency testing assures the accuracy of the test and imposes other
requirements specific to that specialty. However, there is no subspecialty for genetic
testing under CLIA. 30 In the event that a relevant subspecialty does not exist, such as for
genetic testing, there are no specific proficiency standards to which a lab must adhere. 3'
Instead, the lab in question is required to "establish and maintain the accuracy of its
testing procedures," and may do so in a variety of ways; for example, by conducting its
own statistical tests ofpatient results or comparing its test results with another lab. 3 2 For
121 In September 2010, FDA sent letters to five DTC genetic testing companies, requesting that these
companies submit premarket approval applications for their products. See FDA.gov, Medical Devices Letters
to Industry, http://www.fda.govMedicalDevicesResourcesforYoullndustry/ucml I 104.htm, last visitedNov.
18, 2012.
122 Ctrs. for Medicare & Medicaid Servs., CMS Initiatives to Improve Quality of Lab. Testing under
the CLIA Program 1 (2006), available at http://www.cms.hhs.gov/CLIA/downloads/060630.Backgrounder.
rIEG.pdf.
23 Id. A laboratory is defined under CLIA as "a facility for the biological, microbiological, serological,
chemical, immunohematological, hematological, biophysical, cytological, pathological, or other examination
of materials derived from the human body for the purpose of providing information for the diagnosis,
prevention, or treatment of any disease or impairment of, or the assessment of the health of, human beings."
42 C.F.R. § 493.2 (2007). DTC genetic testing companies, which collect "materials derived from the human
body" of consumers "for the purpose of providing" health assessment information arguably fall under this
definition, and are thus subject to CLIA.
124 42 C.F.R. § 493.5 (2007).
25 42 C.F.R. § 493.15 (2007).
126 See Am. Soc'y of Human Genetics Bd. of Dirs., ASHG Statement on Direct-to-Consumer Genetic
Testing in the United States, 81 Am. J. Human Genetics 635, 636 (2007), available at http://www.dnapolicy.
org/resources/ASHG DTC statement.pdf.
127 Novick, supra note 7, at 625.
'28 42 C.F.R. § 493.801 (2007).
29 See 42 C.F.R. § 493.17 (2007).
131 See Am. Soc'y of Human Genetics Bd. of Dirs., ASHG Statement on Direct-to-Consumer Genetic
Testing in the United States, supra note 126.
131 Id
132 42 C.F.R. § 493.801 (a)(2)(ii).
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several years, various groups have lobbied for the addition to CLIA of a subspecialty
for genetic testing in an effort to standardize and improve proficiency requirements for
the genetic testing industry.'33 However, thus far, such efforts have been to no avail.
The creation of a genetic subspecialty under CLIA would doubtless improve the
regulatory environment for genetic testing; however, it is noteworthy that CLIA
(whatever standards it imposes) addresses only the accuracy and not the clinical validity
of tests. Thus, it does not address situations, often encountered in DTC genetic health
tests, where a test may be performed correctly, but the results themselves are misleading.
This could occur, for example, if a test is based on weak association data or is valid
only for a specific ethnic group.
B. FTC Regulation
The Federal Trade Commission (FTC), which regulates food and drug advertising,
has jurisdiction over the advertising of DTC genetic tests. Although it has acknowledged
this jurisdiction, the FTC has not at present regulated the marketing of DTC genetic
health testing.'34 The FTC did, however, release a notice to consumers in 2006 stating
its concerns with DTC genetic tests and recommending that consumers do not use these
tests unless under the supervision of a doctor.'35
C. State Regulation
Local regulation of genetic testing services, and DTC genetic testing services in
particular, varies from state to state. 3 6 For general genetic testing services, only two
states have implemented standards that are more stringent than the federal CLIA
standards. I DTC genetic tests have been regulated more stringently, with several states
either banning their use outright, or requiring a prescription for their use.'38 However,
because most of these tests are marketed online, enforcement of these local regulations
poses a problem.'39
"I http://www.genome.gov, Promoting Safe and Effective Genetic Testing in the United States, http://
www.genome.gov/1 0002402, last visited Nov. 8, 2012.
"I Federal Trade Commission, FTC Facts for Consumers, At-Home Genetic Tests: A Healthy Dose of
Skepticism May Be the Best Prescription I (July 2006), http://www.ftc.gov/bcp/edu/pubs/consumer/health/
hea02.pdf, last visited Nov. 18, 2012.
135 Id.
136 Javett & Hudson, supra note 11.
7 Centers for Medicare and Medicaid Services, CMS Initiatives to Improve Quality of Laboratory
Testing Under the CLIA Program 2 (July 2006), http://www.cms.hhs.gov/CLIA, last visited Nov. 18,
2012; Centers for Medicare and Medicaid Services, List of Exempt States Under the Clinical Laboratory
Improvement Amendments (CLIA), http://www.cms.hhs.gov/CLIA/, last visited Nov. 18, 2012.
13" Gail H. Javitt, Erica Stanley & Kathy Hudson, Direct-to-Consumer Genetic Tests, Government
Oversight, and the First Amendment: What the Government Can (and Can "t) Do to Protect the Public s
Health, 57 Okla. L. Rev. 251, 258 (2004).
119 For example, although DTC genetic tests are banned in some states, the genetic testing service
Navigenics makes no mention on their website of these state restrictions. Navigenies.com, http://www.
navigenics.com/, last visited Nov. 18, 2012. In its Terms of Service, 23andMe places the burden on the
customer by stating that an agreement to the Terms of Service includes a representation that "you are [not] a
person barred from receiving the Services under the laws of the jurisdiction in which you are resident or from
which you use the Services." 23andMe.com, Terms of Service, https://www.23andme.com/about/tos/, last
visited Nov. 18, 2012. Only deCodeMe explains that it will omit certain genetic information for customers
in states where dissemination of this information is illegal; however, this information is buried in the fine
print and customers in these states will likely be surprised when they do not receive full testing information.
deCodeMe.com, deCodeMe Genetic Scan Service Agreement and Informed Consent, http://www.decodeme.
com/service-agreement, last visited Nov. 18, 2012.
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D. FDA Regulation
FDA has jurisdiction under the 1976 Medical Device Amendments to the Food, Drug
and Cosmetic Act to regulate genetic tests as medical devices, and, more specifically,
in vitro diagnostic devices (IVDs).' 40 The steps with which a medical device company
must comply before offering the device to the public vary with the FDA's classification
of the device."'
Class I devices are classified as low-risk and are subject to the least amount of
regulation. 4 Class II. devices are classified as higher-risk and must comply with
premarket notification (510(k)) procedures as well as being subject to additional controls
to assure safety and effectiveness.' 43 Class III devices, classified as highest-risk, must
usually undergo a rigorous premarket approval process in which clinical data are
submitted to the FDA to demonstrate both the safety and effectiveness of the product) 4
1. The Laboratory-Developed Test Exception
Because the clinical effectiveness of many DTC genetic tests has not been established,
these tests would at least initially be classified as Class III devices and would thus be
subject to a rigorous premarket approval process.' 45 However, DTC genetic tests on
the market today have avoided this process because of the "home brew" or laboratory-
developed test (LDT) exception for IVDs. 146 LDTs include tests that are developed in-
house by the company offering the testing service, rather than those that are marketed
to several labs. 47 Because many DTC genetic testing services do indeed develop their
own tests, this exception is relevant. FDA has historically exercised its enforcement
discretion to exempt LDTs from premarket approval, due in part to resource constraints,
but also due in part to FDA's opinion that LDTs were generally "relatively simple, well-
understood tests that diagnosed rare diseases and conditions, and that were intended to
be used by physicians and pathologists in a single institution where they were actively
involved in patient care.' ' 48 Although this is true of many LDTs, it is not true of DTC
predictive genetic tests that are intended to be used independently by consumers and
that evaluate propensity to develop a wide variety of relatively common diseases.
In 1998, FDA increased regulatory oversight of LDTs somewhat by promulgating a
regulation imposing minimal requirements on LDTs with active analyte specific reagents
140 Steve Gutman, The Role of Food and Drug Administration Regulation of In itro Diagnostic
Devices-Applications to Genetics Testing, 45:5 Clin. Chem. 746 (1999).
141 See 21 U.S.C.A. §360.
142 See id. at §360(a)(A)(i).
m See id. at §360(a)(B)(ii).
144 See id. at §360(a)(C)(ii).
'45 Army Huang, FDA Regulation of Genetic Testing: Institutional Reluctance and Public Guardianship,
53 Food & Drug L.J. 555, 562 (1998).
146 See Gutman, supra note 140, at 746.
147 Id.
14 Oversight of Laboratory Developed Tests; Public Meeting; Request for Comments, 75 Fed. Reg.
34,464 (June 17, 2010); see also Council for Responsible Genetics, FDA Investigation into Direct to Consumer
Genetic Testing Companies: An Analysis (2010). Due to resource constraints, administrative agencies may
utilize what is known as enforcement discretion to set priorities for enforcement, or to choose not to institute
enforcement proceedings in certain circumstances. The Supreme Court has found that these decisions are
generally not subject to judicial review under the Administrative Procedure Act. Heckler v Chaney, 470
U.S. 821 (1985).
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(ASRs). 149 In the process of promulgating this regulation FDA considered requiring
heightened scrutiny for predictive genetic home brew ASR tests; however, it did not
do so. 5' The ASR regulation exempts LDTs from premarket notification and premarket
approval requirements, but subjects the test ingredients to general quality controls and
labeling requirements. 5' Although the ASR regulation helps assure the quality of the
product used, it, like the CLIA regulations, does not address the clinical effectiveness
of the test, or the safety concerns arising from the release of test results to the public.
2. Recent FDA Action with Respect to DTC Genetic
Testing Services
In June 2010, FDA demonstrated its intention to discontinue its practice of exempting
DTC genetic testing from premarket approval as LDTs. It did so by sending letters to
five DTC genetic testing companies. 5 2 The letters requested that these companies submit
premarket approval applications to FDA, suggesting that FDA does indeed consider
these tests to be Class III devices.'53 Further, some of the letters stated that FDA does
not consider the DTC genetic tests at issue to be LDTs because "the [tests are] not
developed by and used in a single laboratory."' 54 Although two of the five letters sent
by FDA do not include the statement that FDA does not consider the test at issue to
be an LDT, the fact that these companies nevertheless received a letter suggests that
FDA may be considering excluding all DTC genetic tests from the LDT exemption,
regardless of their definitional status as an LDT.155
This move by FDA would allow for the most comprehensive regulation to date of
DTC genetic tests, and is the appropriate approach, for two reasons. First, although
some DTC genetic tests are "developed and used" in a single laboratory in the sense that
a single laboratory both develops and performs the test, the results of all DTC genetic
tests are "used" not by the testing laboratory, but by the consumer. Under this latter
interpretation, no DTC genetic test falls under the definition of an LDT.56 Further, even
if some DTC genetic tests fit the broader definition of an LDT because they are both
developed and performed in the same lab, DTC genetic tests in general do not conform
to the description of "relatively simple, well-understood tests that diagnose rare diseases
49 Gutman, supra note 140, at 746. The active ingredients of DTC genetic tests fall within FDA's
definition of ASRs, which includes "antibodies, both polyclonal and monoclonal, specific receptor proteins,
ligands, nucleic acid sequences, and similar reagents which, through specific binding or chemical reactions with
substances in a specimen, are intended for use in a diagnostic application for identification and quantification
of an individual chemical substance or ligand in biological specimens." 21 CFR 864.4020(a).
' Medical Devices; Classification/Reclassification; Restricted Devices; Analyte Specific Reagents,
62 Fed. Reg. 62,243 (Nov. 1997).
1St See, e.g., 21 CFR 807.20(a) (requiring registration of devices); 21 CFR 809.10(e) (specifying labeling
requirements); 21 CFR 809.30 (restricting the sale and use of ASR tests but not test results).
" See FDA.gov, Medical Devices Letters to Industry, http://www.fda.gov/MedicalDevices/
ResourcesforYou/lndustry/ucm I 1104.htm. Last visited Nov. 18, 2012. The five companies included Knome,
Inc., 23andMe, Inc., deCode Genetics, Ilumina, Inc., and Navigenics.
"I Council for Responsible Genetics, supra note 148.
151 FDA.gov, Medical Devices Letters to Industry, supra note 152. An LDT is a subset of the category
of medical devices referred to as in vitro diagnostics. In vitro diagnostics are defined as "those reagents,
instruments, and systems intended for use in the diagnosis of disease or other conditions, including a
determination of state of health, in order to cure, mitigate, prevent, or treat disease or its sequelae." An LDT
is an in vitro diagnostic that is developed and used by a single laboratory. 21 CFR 809.3(a).
i Council for Responsible Genetics, supra note 148.
56 This narrower definition of an LDT would result in some non-DTC genetic tests that have historically
fallen within the LDT exception to be excluded; for example, in cases in which a hospital outsources its
diagnostic testing to an outside laboratory. FDA could use its enforcement discretion, however, to exempt
such a subset of tests that do not present the same concerns as DTC genetic tests from the full regulatory
approval process.
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... intended to be used by physicians and pathologists in a single institution where they
[are] actively involved in patient care," the characterization that led the FDA to create a
LDT enforcement exception in the first place. To exempt a subset of DTC genetic tests
from more comprehensive regulation under the LDT enforcement exception because
these tests happen to be developed and performed in the same lab-a feature that has
little relation to the broader concerns surrounding DTC genetic testing-while other
DTC genetic tests are subject to full regulatory review would constitute both an uneven
application of the law and unwise policy. 57 Thus, FDA should regulate all DTC genetic
tests, consistent with the general guidelines provided in Part V.
V. FDA's ROLE IN THE FUTURE OF DTC GENETIC
TEST REGULATION
Given the potential dangers and problems with current DTC genetic testing services,
it is clear that more stringent and consistent regulation is required to ensure that the
products reaching the market are safe, effective, and yield accurate results that can
be safely and properly used by consumers. However, many of the potential avenues
for regulating DTC genetic testing services are either inadequate or pose difficult
implementation and enforcement challenges. CLJA regulation currently does not have
sufficiently specific or consistent proficiency standards for genetic testing due to the
lack of a genetics subspecialty; more importantly, CLIA regulation does not address
the clinical effectiveness of laboratory tests.' FTC may regulate the claims made by
DTC genetic testing services in advertising, but lacks jurisdiction to engage in more
substantive regulation of the safety and effectiveness of the products.'59 Finally, state
regulation lacks consistency and is difficult to enforce given that most providers of
DTC genetic testing services sell their products over the internet.16 °
Because of the inadequacy of or challenges posed by these regulatory schemes,
FDA regulation shows the most potential for providing a comprehensive and consistent
regulatory environment for DTC genetic testing services. Medical device regulation
under the Food, Drug and Cosmetic Act allows FDA to require premarket approval
for the demonstration of safety and effectiveness where necessary, but also allows for
flexibility via the medical device classification system. Thus, if FDA chooses to classify
a specific lower-risk genetic test as Class I or Class II, full premarket approval would not
be required for that test. 6' For example, FDA official Alberto Gutierrez told the public
media that a genetic test for baldness would in all likelihood be classified as a Class I
medical device not requiring premarket approval. 6 2 This statement indicates that FDA
appropriately plans to tailor the degree of regulation to the specific condition being tested.
In addition to distinguishing among conditions, FDA should also distinguish between
"I It would also present a simple means to future DTC genetic testing companies of circumventing
more comprehensive regulatory review - these companies would simply need to ensure that test development
and test execution were carried out in the same lab.
58 42 C.F.R. § 493.801 (2007).
'5 See Genetics and Public Policy Center, Direct-to-Consumer Genetic Testing: Empowering or
Endangering the Public? (July 25,2006), http://www.dnapolicy.org/policy.issue.php?action=detail&issuebrief
id=32, last visited Nov. 18, 2012.
'6 Javitt & Hudson, supra note 1I.
1s1 See 21 U.S.C.A. §360.
162 Alberto Gutierrez, interview with the New York Times, supra note 87.
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predictive and diagnostic genetic tests, and adapt the regulatory process appropriately.63
Further, as the safety and effectiveness of Class III DTC genetic tests are established,
these tests can be down-classified to Class II devices, allowing future marketers of these
products to obtain approval simply by showing that their test is substantially similar
to an approved test under 5 1 0(k) review.164 This regulatory approach strikes the proper
balance of regulation for genetic testing services that pose real risks to the public, while
allowing for innovation and improvement in the genetic testing market by imposing
less stringent regulation on safer tests.
This new approach to the regulation of DTC genetic testing is currently undergoing
its first test. Recently, 23andMe, Inc. applied for de novo 5 10(k) approval for some of
its tests, in response to FDA's 2010 letter stating that FDA does not consider 23andMe,
Inc.'s tests to fall within the LDT exception, and FDA's further determination that
23andMe, Inc.'s products do not qualify for traditional 5 10(k) approval because they
are not substantially equivalent (NSE) to an approved device.'65 De novo 510(k) review
is appropriate when a device is classified as NSE to an approved device and the new
device has been determined to be NSE due to: (1) the lack of an identifiable predicate
device, (2) new intended use, or (3) different technological characteristics that raise new
questions of safety and effectiveness. 6 6 A successful de novo 510(k) application could
result in a down-classification of the tests at issue to Class 1I or I devices; however, in
order to qualify for such a classification 23andMe, Inc. must show both that the tests at
issue are "low to moderate risk and likely to meet the statutory standards for classification
into [C]lass I or [C]lass II under section 513(a)(1) of the [Food Drug and Cosmetic Act]"
and that 23andMe, Inc. "sufficiently understands and is able to explain all of the risks
and benefits of the new device such that all risks can be effectively mitigated through the
application of general and/or special controls."' 67 The de novo 510(k) process provides
a further level of flexibility to the FDA in determining which DTC products should
be subject to the most rigorous Class III testing requirements; however, in light of the
concerns discussed in this article, it would be a mistake for FDA to down-grade all
DTC genetic tests under the 510(k) process without a nuanced consideration of factors
such as the purpose of the test at issue and the condition being tested.
VI. CONCLUSION
Nearly ten years following the sequencing of the human genome project, and after
many years of uncertainty in the regulation of DTC genetic test, FDA has taken the
right approach by beginning to exercise jurisdiction over genetic testing services as
163 A diagnostic test diagnoses the absolute presence or absence of a given condition, while a predictive
test predicts susceptibility (or resistance) to a specific condition. Although many of the concerns discussed
in this article are general to both types of tests, each type raises specific concerns to varying degrees. For
example, while diagnostic tests primarily raise concerns of adverse psychological reactions, predictive tests
primarily raise concerns of ensuring that patients understand the meaning of the test results. Each should
therefore be considered separately when making decisions about the appropriate degree of regulation.
See 21 U.S.C.A. §360(a)(B)(ii).
165 Turna Ray, Genomewe.com, Seeking 510(k) Clearance for Genomic Testing Service, 23andMe
Maintains Direct-to-Consumer Ethos, http://www.genomeweb.com/mdx/seeking-5 1Ok-clearance-genomic-
testing-service-23andme-maintains-direct-consumer, last visited Nov. 18 2012.
66 Draft Guidance for Industry and Food and Drug Administration Staff - De Novo Classification
Process (Evaluation of Automatic Class 1II Designation) (Oct. 3 2011), available at http://www.fda.gov/
MedicalDevices/DeviceRegnlationandGuidanceGuidanceDocuments/ucm273902.htm.
167 Id.
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Class III devices, and should continue to move down this path. 68 This approach will
help ensure that the public has access to safe and effective genetic testing products and
that the important policy and public health issues created by DTC genetic testing are
properly addressed.
168 A draft guidance issued in 2011 suggests that FDA intends to do just this, with three guidance
documents for LDTs planned for the coming years. Draft Guidance for Industry and Food and Drug
Administration Staff- In Vitro Companion Diagnostic Devices (Jul. 12 2011), available at http://www.fda.
gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM262327.pdf.

